Phase 2 Trial of Regorafenib in Recurrent/Metastatic Adenoid Cystic Carcinoma
{{output}}
Purpose: There is a significant need for effective therapies to treat recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC). This study evaluated the multitargeted VEGFR tyrosine kinase inhibitor (TKI) regorafenib in patients... ...
